PassFinals
Gastroenterology & Nutrition

Alcohol-related Liver Disease

Alcohol-related liver disease ranges from reversible steatosis through alcohol-related hepatitis to cirrhosis; assess both the liver stage and alcohol-use disorder because abstinence, nutrition and specialist care change prognosis at every stage.

In a nutshell

Alcohol-related liver disease spans reversible steatosis, potentially life-threatening alcohol-related hepatitis and advanced cirrhosis. Assess alcohol-use disorder, withdrawal risk, nutrition and fibrosis separately. Abstinence is the key intervention; severe hepatitis and cirrhosis require specialist scoring, complication management and coordinated hepatology/addiction care.

Classic presentation

A person with harmful or dependent alcohol use is found to have abnormal liver tests or steatosis, or presents with jaundice and systemic illness from alcohol-related hepatitis. Ascites, haematemesis, melaena or confusion indicate decompensated cirrhosis until proven otherwise.

Key points

  • Fatty liver may improve with abstinence; cirrhosis is established architectural scarring and needs lifelong specialist care.
  • Normal liver blood tests do not exclude cirrhosis; use transient elastography in diagnosed ARLD and according to NICE high-intake thresholds.
  • Treat the alcohol-use disorder and the liver disease together: abstinence support, safe withdrawal, thiamine, nutrition and relapse prevention are core therapy.
  • In suspected alcohol-related hepatitis, exclude infection and competing diagnoses and use a validated severity score before specialist treatment decisions.
  • If corticosteroids are used in severe hepatitis, calculate Lille at day 7 and stop treatment when the score is 0.45 or higher.
  • Cirrhosis needs hepatology follow-up, variceal assessment, six-monthly HCC surveillance and prompt management of ascites, bleeding, infection and encephalopathy.
  • Do not use a simple six-month abstinence rule as the only transplant-referral decision; discuss ongoing hepatic failure early with a transplant service.

First-line investigation

Document alcohol pattern and dependence risk, obtain liver/synthetic-function tests, screen for competing liver disease, and arrange ultrasound plus transient elastography when ARLD or high-risk intake is identified.

Management

Recognise decompensation and withdrawal risk

  • Admit or urgently escalate for gastrointestinal bleeding, new jaundice with confusion, ascites with infection features, renal deterioration, severe withdrawal or suspected Wernicke's encephalopathy.2,1,3

Assess alcohol use, liver injury and fibrosis

  • Record alcohol and withdrawal history, assess liver/synthetic function and competing diagnoses, and arrange ultrasound plus transient elastography when ARLD or high-risk intake is identified.6,4,7,3

Treat abstinence, withdrawal and nutrition together

  • Set abstinence as the goal, involve specialist alcohol services, use a safe withdrawal plan, provide NICE-directed thiamine and optimise nutrition with dietetic support.1,4,5,3

Manage severe hepatitis through hepatology

  • Screen for infection and bleeding, score severity, consider specialist corticosteroids only when appropriate, and stop them for Lille non-response at day 7.1,3,5

Manage cirrhosis complications and transplant need

  • Use hepatology pathways for ascites, SBP, varices, encephalopathy, AKI and acute-on-chronic liver failure; arrange HCC surveillance and early transplant discussion for ongoing hepatic failure.6,9,3,8

Discharge with linked liver and addiction follow-up

  • Provide written diagnosis, abstinence and withdrawal advice, nutrition and medication plans, alcohol-service contact and safety-netting for bleeding, confusion, jaundice, fever, swelling, breathlessness or reduced urine.1,2,5,3

Exam traps

  • Do not assume abnormal liver tests are caused by alcohol; assess viral, autoimmune, metabolic, drug and obstructive causes.
  • Do not assume normal liver blood tests exclude cirrhosis.
  • Do not advise a dependent person to stop alcohol abruptly without assessing withdrawal risk.
  • Thiamine prophylaxis and suspected-Wernicke treatment follow NICE route and BNF/local-protocol guidance; do not delay treatment while waiting for a level.
  • Fever or a raised CRP can occur in alcohol-related hepatitis but does not prove infection; infection screening is still essential.
  • Corticosteroids are specialist treatment for selected severe hepatitis, not routine treatment for steatosis or uncomplicated cirrhosis.
  • Variceal bleeding, ascites with infection, encephalopathy and renal deterioration are emergencies, not routine outpatient symptoms.

Illustrations

The alcohol-related liver disease spectrumDiagram showing progression from reversible steatosis, through alcohol-related hepatitis, to fibrosis and cirrhosis with continued alcohol exposure.PassFinals · original
Histology of alcohol-related steatohepatitisLiver biopsy showing fatty change, ballooned hepatocytes, inflammation and Mallory-Denk-type eosinophilic material in alcohol-related steatohepatitis.Countincr, Wikimedia Commons · CC-BY-SA-2.5
Ultrasound appearance of hepatic steatosisAbdominal ultrasound showing a diffusely bright, echogenic liver consistent with fatty infiltration.Cerevisae, Wikimedia Commons · CC-BY-SA-4.0

Key sources

  1. NICE CG100: Alcohol-use disorders — diagnosis and management of physical complications (Alcohol withdrawal, Wernicke's encephalopathy and alcohol-related liver disease; last updated 2017 and under update review)Published 2 Jun 2010 | Updated 12 Apr 2017
  2. NHS: Alcohol-related liver disease (Symptoms, stages, urgent red flags, testing and prevention)
  3. BASL/BSG ARLD Special Interest Group: Quality standards for alcohol-related liver disease (2023 UK consensus standards for recognition, acute decompensation, alcohol-related hepatitis, nutrition, addiction care and posthospital management)Published 5 Oct 2023
  4. NICE CG115: Alcohol-use disorders — harmful drinking and alcohol dependence (Validated alcohol-use assessment, abstinence goal and specialist alcohol-support pathways)
  5. NHS: Alcohol-related liver disease — treatment (Abstinence, withdrawal safety, relapse prevention, nutrition, hospital treatment and transplant overview)
  6. NICE NG50: Cirrhosis in over 16s — assessment and management (Transient elastography, specialist referral, MELD monitoring, varices and HCC surveillance; updated 2023)Published 6 Jul 2016 | Updated 8 Sept 2023
  7. NHS: Alcohol-related liver disease — diagnosis (Limits of liver blood tests, imaging, elastography and biopsy)
  8. NHS: Alcohol-related liver disease — complications (Portal hypertension, encephalopathy, infection and liver-cancer complications)
  9. NICE QS152: Liver disease — HCC surveillance (Six-monthly HCC surveillance quality statement for adults with cirrhosis)Published 29 Jun 2017

This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.